In February 2015, a deputy executive secretary of the Nevada State Board of Pharmacy contacted a pharmacy company called VetSource — an Oregon-based veterinary medication delivery platform operating in all fifty states — and told a company employee that he was certain VetSource’s business model violated Nevada’s anti-kickback statute. He communicated this conclusion before reviewing any documentation VetSource had offered to provide. He also told her the Board would win if VetSource tried to fight.

He was wrong on both counts.

What followed was two years of litigation, two cease-and-desist letters, a formal license revocation proceeding, a federal antitrust lawsuit, a parallel state court action, an appeal to the Nevada Supreme Court, and a settlement that required legislative and regulatory changes to fully implement. By February 2017, the case was over. VetSource continued operating in Nevada. The Board’s accusation was rescinded. And the anti-kickback question the Board had been so certain about was never actually decided.

That last part is important. Because the legal infrastructure the Nevada Board tried to deploy against VetSource — state anti-kickback statutes, practice act fee-splitting prohibitions, and the regulatory authority of professional licensing boards — is the same infrastructure that has never been deployed against the corporate teleradiology platforms operating revenue-sharing arrangements in the same states, under the same laws, at a scale that dwarfs anything VetSource ever did.

The enforcement gap is not a gap in the law. It is a gap in institutional will, structural conflict of interest, and — critically — in who has the legal standing to enforce without becoming the target.

What VetSource Actually Did

VetSource, operating as Strategic Pharmaceutical Solutions, Inc., ran an outsourced pharmacy delivery model for veterinarians. The mechanics were straightforward: a veterinarian prescribing a medication could contract with VetSource to fill and ship the prescription directly to the pet owner. VetSource would sell the medication wholesale to the veterinarian, the veterinarian would set a retail price and sell to the client, and VetSource would handle fulfillment and delivery. The veterinarian’s profit margin — the spread between what they paid VetSource and what they charged the client — remained with the veterinarian.

VetSource charged the veterinarian a pharmacy processing fee and delivery charge. It collected the full transaction amount from the pet owner and deposited the proceeds into the veterinarian’s merchant account, from which VetSource deducted its fees. The veterinarian kept the remainder.

The Nevada Pharmacy Board characterized this arrangement as a kickback — specifically, as remuneration paid to veterinarians in exchange for directing prescriptions to VetSource rather than to competing pharmacies. VetSource argued, with considerable force, that the veterinarian’s margin was not a payment from VetSource at all. It was the veterinarian’s own markup on a product the veterinarian had purchased and resold. VetSource received no remuneration for referrals. It charged a disclosed, fair-market-value fee for services rendered.

At least eight other state pharmacy boards had reviewed the VetSource model and found it lawful. None had found it unlawful.

The Timeline of a Regulatory Overcorrection

At least two other outsourced pharmacy competitors had already been forced out of the Nevada market by earlier Board actions before VetSource fought back. VetSource was the first company large enough, and well-capitalized enough, to turn the regulatory proceeding into an antitrust case.

Why VetSource Won — and What It Does Not Mean

The critical fact about the VetSource outcome is what it did not decide. The case was not resolved on the merits of the anti-kickback question. No court ever ruled that VetSource’s business model complied with Nevada’s anti-kickback statute. No court ever ruled that the arrangement between VetSource and its contracted veterinarians was or was not a prohibited remuneration for referrals.

VetSource won on antitrust grounds. The Board — composed of six licensed pharmacists who actively competed in the pet medication market — was held to be exactly the kind of market-participant-controlled regulatory body that the Supreme Court had warned about in NC Dental Examiners ten months before the complaint was filed. That decision held that state regulatory agencies composed primarily of active market participants are not entitled to state-action immunity from federal antitrust laws unless their anticompetitive actions are actively supervised by a politically accountable state official. The Nevada Board had no such supervision. No politically accountable state official had the authority to review or veto the Board’s decisions.

The Board was using the right law against the wrong company, deployed by the wrong enforcer, without the oversight required to make that enforcement legitimate.

The settlement’s requirement of legislative and regulatory changes further undercuts the narrative that VetSource simply vindicated the legality of its revenue-sharing model. Nevada’s legislature had to act. The underlying regulatory tension was real enough that the law itself needed clarification — not because the anti-kickback statutes didn’t apply, but because the question of how they applied to this specific delivery model was unresolved.

The Business Model the Law Was Written For

VetSource’s model, at its most aggressive reading, involved a veterinarian earning a markup on medications dispensed through a third-party platform. The platform received a processing fee. The veterinarian received the margin. A pharmacy board saw that structure and called it a kickback.

Now consider the teleradiology model that Part 1 of this series examined.

A veterinary practice contracts with a teleradiology platform. The platform provides PACS software, image storage, and reading services. The contract grants the platform a perpetual, irrevocable license to the practice’s diagnostic images. The platform offers volume-based loyalty incentives — discounts, rebates, or service credits — that increase with the volume of cases submitted. The practice earns no explicit “margin” in the VetSource sense, but the economic relationship is structured so that increased referral volume produces increased financial benefit to the practice in the form of reduced costs, platform subsidies, or loyalty program rewards.

The Nevada Pharmacy Board looked at VetSource’s model and saw remuneration flowing from the platform to the referral source in exchange for directing patient volume. The structure of the dominant teleradiology platforms is not categorically different. The remuneration is less explicit. The referral relationship is dressed in the language of service agreements and clinical partnerships. But the economic logic — send us cases, receive value — is the same logic that triggered two cease-and-desist letters, a license revocation proceeding, and two years of federal litigation when it appeared in the pet medication delivery context.

No state veterinary board has ever opened a formal proceeding on this question.

A Commodity Markup vs. a Professional Fee Inversion: Why Teleradiology Is More Exposed, Not Less

There is a distinction between the VetSource model and the teleradiology model that the anti-kickback analysis above does not fully capture — and that distinction cuts against the platforms, not in their favor.

VetSource was moving a commodity. The medications it dispensed were manufactured pharmaceutical products with defined wholesale prices, available from multiple suppliers, fungible across vendors. The veterinarian’s markup was a retail margin on a tangible good. Courts and regulators have historically extended some tolerance to product distribution margins because the economics are transparent — the cost of goods is knowable, the markup is the veterinarian’s commercial decision, and the product itself is the same regardless of who fills the prescription.

Teleradiology is not a commodity. What is being referred when a veterinary practice submits a case to a teleradiology platform is the interpretation of a diagnostic imaging study — a professional medical act, performed by a board-certified veterinary radiologist holding the Diplomate of the American College of Veterinary Radiology credential. The DACVR requires completion of an accredited three-year residency following veterinary school, passage of a rigorous two-part board examination, and demonstrated clinical and academic competency evaluated by the profession’s own credentialing body. The credential exists precisely because diagnostic imaging interpretation is a specialized discipline that general practitioners are not trained to perform at the same level.

In many corporate platform arrangements, the board-certified radiologist who performs the interpretation has more post-graduate specialty training than the general practitioner whose name is on the practice and who owns the client relationship. The referring veterinarian in a busy mixed-practice clinic may have completed no formal radiology training beyond the core curriculum of veterinary school. The radiologist reading that practice’s cases may have spent three additional years in residency specifically to develop the interpretive skills the referring doctor is billing for.

That credential and training differential matters to the anti-kickback analysis because it clarifies what is actually being bought and sold. The platform is selling a professional medical service — one that requires specialty credentials, ongoing continuing education, and malpractice exposure to deliver. The referring practice is buying that service, marking it up, and retaining the spread.

The markup inversion is the mechanism. A teleradiology platform’s reading fee for a standard study typically ranges from $75 to $150 depending on species, modality, and complexity. That fee compensates a board-certified specialist for a professional act requiring years of credentialed training. The referring practice then bills the client for that same interpretation — often at more than double the cost, with the markup retained entirely by the practice that contributed nothing to the interpretive work. In many cases the practice’s margin on a single teleradiology case exceeds the radiologist’s fee for performing it.

This structure has a specific name in human medicine. The Centers for Medicare and Medicaid Services Anti-Markup Rule, codified at 42 C.F.R. § 415.130, prohibits a supervising physician from billing Medicare for a diagnostic test at more than the performing physician’s net charge when the performing physician is not employed by or in the same group practice as the billing physician. The rule exists because CMS recognized exactly this dynamic: a non-specialist billing at a marked-up rate for a specialist’s professional services, and retaining the spread, is an economic arrangement that is structurally indistinguishable from paying for referrals with the referring provider’s own markup as the currency.

Veterinary medicine has no federal equivalent of the CMS Anti-Markup Rule, because there is no Medicare program for companion animals. But the absence of a federal analog does not render the state anti-kickback statutes inapplicable. Those statutes prohibit remuneration for referrals. They do not limit their application to cases where a federal billing rule has also been violated. A markup that more than doubles the professional fee of the credentialed specialist who actually performed the service is remuneration. The referral is the case submission. The statutes that the Nevada Pharmacy Board cited against VetSource — and the broader anti-kickback and fee-splitting provisions across the states examined in Part 1 — reach this arrangement at least as readily as they reach a veterinarian’s margin on a medication dispensed through a third-party pharmacy platform.

The professional character of the service being marked up does not insulate the arrangement. It indicts it more directly. The anti-kickback statutes in veterinary practice acts are calibrated specifically to protect the integrity of professional medical referrals — the decisions a licensed practitioner makes about where to send a patient’s case for specialized care. When the economic structure of a platform relationship means that a general practitioner earns more from marking up a radiologist’s fee than the radiologist earns from performing the interpretation, the professional referral decision and the financial incentive have become the same decision. That is the harm the statutes were written to prevent.

The Statute-by-Statute Exposure

Part 1 of this series documented the anti-kickback and fee-splitting provisions across seven states. Those statutes apply with equal force to teleradiology arrangements. The VetSource litigation is instructive precisely because the Nevada Board cited the same category of law — state anti-kickback regulation — that governs veterinary referral relationships in those states.

The Enforcer Problem — and Why It Matters

The VetSource case did not establish that veterinary revenue-sharing arrangements are legal. It established that a regulatory board composed of market participants cannot use anti-kickback law as an anticompetitive weapon without active state supervision. That is a lesson about the identity of the enforcer, not the validity of the underlying law.

The question for teleradiology enforcement is therefore not whether the statutes apply. It is who can enforce them without triggering the same antitrust exposure that defeated the Nevada Board.

There are exactly four categories of enforcers who do not face the NC Dental Examiners problem.

State Attorneys General

A state AG is not a market participant. A state AG is a constitutionally or statutorily designated officer of the state with plenary authority to enforce consumer protection, unfair trade practices, and professional licensing laws. No court has ever applied NC Dental Examiners to limit AG enforcement authority. An AG investigating veterinary teleradiology fee-splitting arrangements under a state anti-kickback statute is exercising exactly the kind of politically accountable state authority that NC Dental Examiners said was missing from the Nevada Board’s conduct. The defense that stopped the Nevada Board does not exist for a state AG.

State AGs have enforcement authority under consumer protection statutes in every state. Many of those statutes extend to unlawful business practices in licensed professions. An AG who determined that a national teleradiology platform was paying de facto kickbacks to veterinary practices — structured as volume discounts, loyalty program credits, or platform subsidies — would have statutory tools available that the Nevada Pharmacy Board never possessed.

The FTC

The Federal Trade Commission enforces Section 5 of the FTC Act, which prohibits unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce. The FTC was the agency that brought the original action in NC Dental Examiners — the case VetSource used as a sword against the Nevada Board. The FTC knows this area of law better than any regulatory agency in the country. Corporate veterinary consolidation — the acquisition of practices, laboratories, imaging platforms, and reading services by entities like Mars, IDEXX, and their private equity-backed competitors — is exactly the kind of market structure the FTC is equipped to examine for anticompetitive effects. The FTC’s Premerger Notification Program already tracks the consolidation wave. The enforcement step from merger review to referral arrangement investigation is not a long one.

Properly-Constituted State Veterinary Boards

The Nevada Pharmacy Board lost because it was composed of market participants acting without adequate state supervision. State veterinary boards are not immune to the same structural problem — a board composed of practitioners with existing financial relationships with the dominant teleradiology platforms faces its own conflict of interest questions. But a veterinary board that is properly supervised by a politically accountable state official, acting pursuant to a clearly articulated state policy, and composed of members without direct financial relationships with the entities under investigation, does not face the NC Dental Examiners problem. The legal mechanism exists. The question is whether any state veterinary board has the institutional will and structural independence to use it.

Private Litigants

The Sherman Act, the statutes VetSource invoked against the Nevada Board, provides a private right of action for antitrust injury. State unfair trade practices acts in most jurisdictions provide similar private remedies. A veterinary practice that was excluded from a preferred teleradiology platform, or that suffered competitive disadvantage because a competitor practice received preferred pricing in exchange for volume commitments, would have a cognizable injury under existing antitrust frameworks. Private antitrust litigation in professional services markets is not unprecedented. It is expensive, slow, and uncertain — but it is available, and it does not require a government agency to act first.

The Asymmetry That Defines the Gap

The Nevada Pharmacy Board moved against VetSource — a company with a documented, transparent, fair-market-value pricing structure reviewed and approved by at least eight other state pharmacy boards — with two cease-and-desist letters, a license revocation proceeding, communications to veterinarians warning them away from the platform, and two years of litigation.

The conduct that triggered all of that enforcement energy was a veterinarian earning a disclosed retail margin on medication sales through a third-party fulfillment platform.

The conduct that has never triggered any formal enforcement proceeding by any state veterinary board involves national platforms whose integrated PACS ecosystems, volume-based loyalty programs, perpetual image license provisions, and liability disclaimers function together to create financial relationships between the platform and the referring practice that are structurally indistinguishable from the remuneration arrangements the anti-kickback statutes were written to prohibit.

VetSource was small enough to threaten and large enough to fight back. The outcome of that fight — an antitrust victory that required the state of Nevada to change its laws — has since been read by the industry as proof that anti-kickback enforcement in veterinary medicine is legally risky for the enforcer.

That reading is not wrong. But it is incomplete. It is only legally risky for the wrong enforcer. The Nevada Pharmacy Board was structurally disqualified from bringing that case under NC Dental Examiners. A state attorney general is not.

What Proper Enforcement Would Look Like

An enforcement action against a national teleradiology platform for fee-splitting under a state anti-kickback statute would not look like the Nevada Board’s proceeding against VetSource. It would not be initiated by a regulatory body composed of market participants. It would not be vulnerable to the antitrust counterattack that ended the Nevada case. It would look more like what the Department of Justice and the Securities and Exchange Commission did in the US Compounding case — a subject Part 3 of this series examines in detail — where federal authorities pursued a veterinary pharmaceutical kickback scheme through criminal and civil channels simultaneously, producing guilty pleas, a corporate conviction, and disgorgement of profits.

The legal theory would be straightforward. The investigation would document the economic relationship between the platform and the referring practices: the volume thresholds, the loyalty incentives, the pricing structures, and the referral patterns. It would compare that economic relationship to the text of the applicable state anti-kickback statute. It would assess whether the remuneration — however labeled — was provided in exchange for directing cases to the platform. It would then apply the same legal analysis the Nevada Board attempted, conducted by an enforcer who cannot be sued for applying it.

None of that has happened. Not once. Not in any state. Not against any teleradiology platform. Not against IDEXX, which reported $3.898 billion in revenue in 2024, a significant portion of which flows through the integrated platform relationships this series has been examining. Not against the private-equity-backed consolidators who have assembled reading service networks across dozens of states. Not against any of the corporate veterinary entities whose platform arrangements with the practices they own or with which they have preferred relationships create referral economics that state anti-kickback statutes were designed to reach.

The Gap Is a Choice

The VetSource case did not close the enforcement gap. It clarified it. It established that a regulatory board composed of competitor pharmacists cannot use anti-kickback law to exclude a transparent, documented, multiply-approved platform from the market. It left entirely open the question of what happens when a properly constituted enforcer — a state AG, the FTC, or a supervised veterinary board — applies that same law to a platform whose revenue-sharing arrangements are less transparent, less documented, and operating at a scale that makes VetSource’s Nevada revenue look like rounding error.

The law that the Nevada Board tried and failed to enforce is still on the books. In Nevada and in every state whose anti-kickback and fee-splitting provisions Part 1 of this series examined. Those statutes do not have expiration dates. They do not have carveouts for teleradiology. They do not exempt arrangements that are labeled as loyalty programs rather than referral fees.

The enforcement gap is not a gap in the law. It is a gap in the institutional decision to enforce it. And unlike the Nevada Pharmacy Board, the enforcers who could close that gap — state attorneys general, the FTC, and the Department of Justice — have not yet been stopped by an antitrust counterclaim. They have simply not yet started.